Melflufen (Melphalan flufenamide) hydrochloride, a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen hydrochloride shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen hydrochloride induces irreversible DNA damage and cytotoxicity in MM cells . In Vitro Melflufen (Melphalan flufenamide) hydrochloride (0.5-10 μM; 24 hours) decreases viability of MM.1S, INA-6, RPMI-8226, MM.1R, Dox-40, ARP-1, and ANBL-6 cells in a concentration-dependent manner. Melflufen hydrochloride induces apoptosis in MM.1S cells. Melflufen hydrochloride also is a potent activator of exosome secretion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Multiple myeloma cells: MM.1S, INA-6, RPMI-8226, MM.1R, Dox-40, ARP-1, ANBL-6 cells Concentration: 0.5, 1, 3, 5, 10 μM Incubation Time: 24 hours Result: A significant concentration-dependent decrease in viability of all cell lines was observed. In Vivo Melflufen (Melphalan flufenamide) hydrochloride (3 mg/kg; i.v.; twice-weekly for two weeks) shows anti-MM activity in xenograft mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: CB-17 SCID mice (human plasmacytoma MM.1S xenograft mouse model) Dosage: 3 mg/kg Administration: 1.v.; twice-weekly for two weeks Result: Significantly inhibited MM tumor growth and prolonged survival of mice. Form:Solid